Thymulin
Also known as: Zinc-FTS, Facteur Thymique Serique, Thymic Peptide, Serum Thymic Factor
Thymulin is a zinc-dependent thymic nonapeptide. Older small human studies include positive rheumatoid-arthritis findings and a neutral multiple-sclerosis trial; general anti-aging dosing and long-term safety remain unestablished.
Quick Facts
What Is Thymulin?
Thymulin is the biologically active zinc-bound form of serum thymic factor (FTS), a nine-amino-acid peptide. The original zinc-binding study distinguished inactive zinc-free FTS from the active complex using a biological assay.
Thymulin is not thymosin alpha-1 or the thymalin extract. Evidence and dosing for those products cannot be transferred simply because they also concern the thymus.
How Does Thymulin Work?
The original biochemical work supports zinc’s role in thymulin activity. A small human zinc study found changes in measured thymulin activity after zinc supplementation in selected participants.
The zinc intervention was not a trial of injected thymulin for anti-aging. It does not establish that everyone needs a fixed zinc dose or that raising a laboratory activity measure reverses immune aging.
Research & Clinical Evidence
An older rheumatoid-arthritis report describes two randomized double-blind trials of nonathymulin. The 5 mg/day arm had a favorable global response, reported as 56% versus 17% with placebo, while immunological measures did not show clear differences. The indexed abstract does not supply enough detail to reconstruct a general administration protocol.
A separate 40-patient multiple-sclerosis trial used subcutaneous treatment for six months with a further six-month follow-up. It did not show a disability benefit and reported no significant side effects. This neutral trial should accompany the favorable rheumatoid-arthritis signal.
| Source | Design | Finding and limit |
|---|---|---|
| Rheumatoid arthritis | Two reported randomized double-blind trials | Positive global response at one dose; older abstract-level evidence here. |
| Multiple sclerosis | 40 patients; six-month treatment | No disability benefit; small study does not settle rare or long-term harms. |
| Zinc and thymulin activity | Small human supplementation experiments | Biomarker activity; not thymulin anti-aging treatment. |
Potential Benefits
The rheumatoid-arthritis finding is a useful human signal for further investigation. It does not establish prevention of infections, cancer protection or broad immune rejuvenation in otherwise healthy older adults.
The neutral multiple-sclerosis trial also shows why an immunological rationale cannot be treated as proof of benefit across autoimmune diseases.
Dosage & Administration
The arthritis abstract reports 1, 5 and 10 mg/day research exposures. Route, full sample details and duration were not verified from an accessible full paper in this pass. The MS report describes a separate subcutaneous trial.
These older condition-specific studies do not validate a universal microgram injection schedule, a 4–12-week anti-aging cycle or routine zinc co-supplementation. They should not be converted into a personal protocol.
Side Effects & Safety Profile
The older arthritis report describes minimal adverse effects and the MS trial reported no significant side effects. Small and limited-duration studies cannot establish zero risk or indefinite safety.
Autoimmune conditions require disease-specific evidence: a favorable finding in arthritis does not establish suitability for every immune disorder. The reviewed sources do not provide a general pregnancy, interaction or long-term cancer-safety assessment.
Source Review and Evidence Limits
Original indexed arthritis, MS and zinc-binding abstracts were read; the original JCI zinc paper was obtained and its abstract/context read. The arthritis archive supplied scanned-page access, but its attempted PDF retrieval returned HTML; the full trial paper was not verified. No current comprehensive US approval determination was made. This is an editorial source assessment, not clinician or whole-family certification.
Frequently Asked Questions About Thymulin
Thymulin is a zinc-dependent thymic peptide involved in immune signaling. Older small human studies show some positive clinical and biomarker findings, but do not establish broad protection against infections or universal immune restoration.
Age-related thymic changes are a research rationale, not evidence that administering thymulin reverses aging. Circulating activity and clinical immune function are different outcomes.
Reversal of immune aging in healthy people is not established by the reviewed sources. The small zinc experiments and condition-specific trials do not answer that question.
Zinc is part of active thymulin, but biochemical dependence does not establish that everyone should take a fixed supplement dose. The reviewed human zinc study was a selected-participant supplementation experiment, not a general thymulin protocol.
There is no universal autoimmune-safety conclusion. Older arthritis studies reported a favorable signal, whereas a 40-patient MS trial did not improve disability. These findings do not establish benefit or safety across all autoimmune diseases.
Related Peptides
Continue exploring Thymulin
Search all related references →Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.